GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

GSK said it is making its largest manufacturing investment in the US yet, allocating $800 million to upgrade its vaccine ...

The growth of the DEE treatment market can be attributed to the increasing prevalence of developmental and epileptic ...

The growth of the Chronic Hepatitis B Virus Testing market can be attributed to several key factors, including significant ...

The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, AbbVie expanded a ...

Treatment MarketThe global castration-resistant prostate cancer (CRPC) treatment market is poised for substantial growth, ...

UK pharmaceutical giant GlaxoSmithKline (GSK) has announced a five year collaboration with Cambridge University despite claims that a discontinued version of its heartburn drug causes cancer. GSK is ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.50. The company’s shares opened today at ...

Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on October 9. Graham ...

This content was published on Oct 26, 2024 The Swiss Federal Democratic Union (EDU) has handed in referendum signatures to seek a vote to prevent the Eurovision Song Contest (ESC) from taking ...

Last week, GlaxoSmithKline and Northwestern University filed separate lawsuits against Moderna, accusing its mRNA-based vaccines of ...

Despite strong cash flow and organic growth in most of its key brands, high leverage and mixed valuation ratios lead to a ...